{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:56:04Z","timestamp":1790052964121,"version":"4.0.1"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Research Foundation of Korea(NRF) grant funded by the Korea governmen","award":["RS-2023-00252824"],"award-info":[{"award-number":["RS-2023-00252824"]}]},{"DOI":"10.13039\/501100002631","name":"Gachon University","doi-asserted-by":"publisher","award":["GCU-2016-5181"],"award-info":[{"award-number":["GCU-2016-5181"]}],"id":[{"id":"10.13039\/501100002631","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12272-025-01538-0","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T10:44:53Z","timestamp":1744627493000},"page":"333-350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["PET tracer development for imaging \u03b1-synucleinopathies"],"prefix":"10.1007","volume":"48","author":[{"given":"Mohammad Maqusood","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Hak","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobia","family":"Wasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6029-8553","authenticated-orcid":false,"given":"Sang-Yoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"1538_CR1","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s00259-017-3704-6","volume":"44","author":"EO Aboagye","year":"2017","unstructured":"Aboagye EO, Kraeber-Bodere F (2017) Highlights lecture EANM 2016: \u201cembracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicine.\u201d Eur J Nucl Med Mol Imaging 44:1559\u20131574. https:\/\/doi.org\/10.1007\/s00259-017-3704-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1538_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3233\/jad-2004-6412","volume":"6","author":"MA Alim","year":"2004","unstructured":"Alim MA, Ma QL, Takeda K, Aizawa T, Matsubara M, Nakamura M, Asada A, Saito T, Kaji H, Yoshii M, Hisanaga S, Ueda K (2004) Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein. J Alzheimers Dis 6:435\u2013442. https:\/\/doi.org\/10.3233\/jad-2004-6412","journal-title":"J Alzheimers Dis"},{"key":"1538_CR3","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/mds.28984","volume":"37","author":"OM Alzghool","year":"2022","unstructured":"Alzghool OM, van Dongen G, van de Giessen E, Schoonmade L, Beaino W (2022) alpha-Synuclein radiotracer development and in vivo imaging: recent advancements and new perspectives. Mov Disord 37:936\u2013948. https:\/\/doi.org\/10.1002\/mds.28984","journal-title":"Mov Disord"},{"key":"1538_CR4","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1242\/jcs.180737","volume":"129","author":"PR Angelova","year":"2016","unstructured":"Angelova PR, Ludtmann MH, Horrocks MH, Negoda A, Cremades N, Klenerman D, Dobson CM, Wood NW, Pavlov EV, Gandhi S, Abramov AY (2016) Ca2+ is a key factor in alpha-synuclein-induced neurotoxicity. J Cell Sci 129:1792\u20131801. https:\/\/doi.org\/10.1242\/jcs.180737","journal-title":"J Cell Sci"},{"key":"1538_CR5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/ene.13624","volume":"25","author":"A Antonini","year":"2018","unstructured":"Antonini A, Tinazzi M, Abbruzzese G, Berardelli A, Chaudhuri KR, Defazio G, Ferreira J, Martinez-Martin P, Trenkwalder C, Rascol O (2018) Pain in Parkinson\u2019s disease: facts and uncertainties. Eur J Neurol 25:917-e69. https:\/\/doi.org\/10.1111\/ene.13624","journal-title":"Eur J Neurol"},{"key":"1538_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055031","volume":"8","author":"DP Bagchi","year":"2013","unstructured":"Bagchi DP, Yu L, Perlmutter JS, Xu J, Mach RH, Tu Z, Kotzbauer PT (2013) Binding of the radioligand SIL23 to alpha-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS ONE 8:e55031. https:\/\/doi.org\/10.1371\/journal.pone.0055031","journal-title":"PLoS ONE"},{"key":"1538_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Schapira AHV (2020) Parkinson disease. Eur J Neurol 27:27\u201342. https:\/\/doi.org\/10.1111\/ene.14108","journal-title":"Eur J Neurol"},{"key":"1538_CR8","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.bbapap.2010.04.001","volume":"1804","author":"M Biancalana","year":"2010","unstructured":"Biancalana M, Koide S (2010) Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta 1804:1405\u201312. https:\/\/doi.org\/10.1016\/j.bbapap.2010.04.001","journal-title":"Biochim Biophys Acta"},{"key":"1538_CR9","doi-asserted-by":"publisher","first-page":"24774","DOI":"10.1021\/acsomega.4c01301","volume":"9","author":"F Bonanno","year":"2024","unstructured":"Bonanno F, Saw RS, Bleher D, Papadopoulos I, Bowden GD, Bjerregaard-Andersen K, Windhorst AD, Pichler BJ, Herfert K, Maurer A (2024) Advancing Parkinson\u2019s disease diagnostics: the potential of arylpyrazolethiazole derivatives for imaging alpha-synuclein aggregates. ACS Omega 9:24774\u201324788. https:\/\/doi.org\/10.1021\/acsomega.4c01301","journal-title":"ACS Omega"},{"key":"1538_CR10","first-page":"1","volume":"201","author":"H Braak","year":"2009","unstructured":"Braak H, Del Tredici K (2009) Neuroanatomy and pathology of sporadic Parkinson\u2019s disease. Adv Anat Embryol Cell Biol 201:1\u2013119","journal-title":"Adv Anat Embryol Cell Biol"},{"key":"1538_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res 318:121\u201334. https:\/\/doi.org\/10.1007\/s00441-004-0956-9","journal-title":"Cell Tissue Res"},{"key":"1538_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nrn3887","volume":"16","author":"J Brettschneider","year":"2015","unstructured":"Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ (2015) Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci 16:109\u201320. https:\/\/doi.org\/10.1038\/nrn3887","journal-title":"Nat Rev Neurosci"},{"issue":"Suppl 1","key":"1538_CR13","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.expneurol.2003.08.008","volume":"184","author":"DJ Brooks","year":"2003","unstructured":"Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, Prentice R, Shults CW, Stoessl AJ (2003) Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson\u2019s disease. Exp Neurol 184(Suppl 1):S68-79. https:\/\/doi.org\/10.1016\/j.expneurol.2003.08.008","journal-title":"Exp Neurol"},{"key":"1538_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V (2023) Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 14:176. https:\/\/doi.org\/10.1038\/s41419-023-05672-9","journal-title":"Cell Death Dis"},{"key":"1538_CR15","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1073\/pnas.1218424110","volume":"110","author":"BK Choi","year":"2013","unstructured":"Choi BK, Choi MG, Kim JY, Yang Y, Lai Y, Kweon DH, Lee NK, Shin YK (2013) Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc Natl Acad Sci U S A 110:4087\u201392. https:\/\/doi.org\/10.1073\/pnas.1218424110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1538_CR16","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1021\/acs.jmedchem.5b00571","volume":"58","author":"W Chu","year":"2015","unstructured":"Chu W, Zhou D, Gaba V, Liu J, Li S, Peng X, Xu J, Dhavale D, Bagchi DP, D\u2019avignon A, Shakerdge NB, Bacskai BJ, Tu Z, Kotzbauer PT, Mach RH (2015) Design, synthesis, and characterization of 3-(Benzylidene)indolin-2-one derivatives as ligands for alpha-synuclein fibrils. J Med Chem 58:6002\u201317. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00571","journal-title":"J Med Chem"},{"key":"1538_CR17","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1523\/JNEUROSCI.5367-11.2012","volume":"32","author":"E Colla","year":"2012","unstructured":"Colla E, Coune P, Liu Y, Pletnikova O, Troncoso JC, Iwatsubo T, Schneider BL, Lee MK (2012) Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo. J Neurosci 32:3306\u201320. https:\/\/doi.org\/10.1523\/JNEUROSCI.5367-11.2012","journal-title":"J Neurosci"},{"key":"1538_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jamaneurol.2020.4152","volume":"78","author":"GUND Collaborators","year":"2021","unstructured":"Collaborators GUND, Feigin VL, Vos T, Alahdab F, Amit AML, Barnighausen TW, Beghi E, Beheshti M, Chavan PP, Criqui MH, Desai R, Dhamminda Dharmaratne S, Dorsey ER, Wilder Eagan A, Elgendy IY, Filip I, Giampaoli S, Giussani G, Hafezi-Nejad N, Hole MK, Ikeda T, Owens Johnson C, Kalani R, Khatab K, Khubchandani J, Kim D, Koroshetz WJ, Krishnamoorthy V, Krishnamurthi RV, Liu X, Lo WD, Logroscino G, Mensah GA, Miller TR, Mohammed S, Mokdad AH, Moradi-Lakeh M, Morrison SD, Shivamurthy VKN, Naghavi M, Nichols E, Norrving B, Odell CM, Pupillo E, Radfar A, Roth GA, Shafieesabet A, Sheikh A, Sheikhbahaei S, Shin JI, Singh JA, Steiner TJ, Stovner LJ, Wallin MT, Weiss J, Wu C, Zunt JR, Adelson JD, Murray CJL (2021) Burden of neurological disorders across the US from 1990\u20132017: a global burden of disease study. JAMA Neurol 78:165\u2013176. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4152","journal-title":"JAMA Neurol"},{"key":"1538_CR19","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cell.2012.03.037","volume":"149","author":"N Cremades","year":"2012","unstructured":"Cremades N, Cohen SI, Deas E, Abramov AY, Chen AY, Orte A, Sandal M, Clarke RW, Dunne P, Aprile FA, Bertoncini CW, Wood NW, Knowles TP, Dobson CM, Klenerman D (2012) Direct observation of the interconversion of normal and toxic forms of alpha-synuclein. Cell 149:1048\u201359. https:\/\/doi.org\/10.1016\/j.cell.2012.03.037","journal-title":"Cell"},{"key":"1538_CR20","doi-asserted-by":"publisher","first-page":"9220","DOI":"10.1523\/JNEUROSCI.2617-07.2007","volume":"27","author":"KM Danzer","year":"2007","unstructured":"Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27:9220\u201332. https:\/\/doi.org\/10.1523\/JNEUROSCI.2617-07.2007","journal-title":"J Neurosci"},{"key":"1538_CR21","doi-asserted-by":"publisher","first-page":"31450","DOI":"10.1021\/acsomega.3c04292","volume":"8","author":"A Di Nanni","year":"2023","unstructured":"Di Nanni A, Saw RS, Battisti UM, Bowden GD, Boeckermann A, Bjerregaard-Andersen K, Pichler BJ, Herfert K, Herth MM, Maurer A (2023) A fluorescent probe as a lead compound for a selective alpha-Synuclein PET tracer: development of a library of 2-styrylbenzothiazoles and biological evaluation of [(18)F]PFSB and [(18)F]MFSB. ACS Omega 8:31450\u201331467. https:\/\/doi.org\/10.1021\/acsomega.3c04292","journal-title":"ACS Omega"},{"key":"1538_CR22","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3233\/JPD-130247","volume":"3","author":"JL Eberling","year":"2013","unstructured":"Eberling JL, Dave KD, Frasier MA (2013) alpha-synuclein imaging: a critical need for Parkinson\u2019s disease research. J Parkinsons Dis 3:565\u20137. https:\/\/doi.org\/10.3233\/JPD-130247","journal-title":"J Parkinsons Dis"},{"issue":"2540\u20132557","key":"1538_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2024.05.006","volume":"112","author":"H Endo","year":"2024","unstructured":"Endo H, Ono M, Takado Y, Matsuoka K, Takahashi M, Tagai K, Kataoka Y, Hirata K, Takahata K, Seki C, Kokubo N, Fujinaga M, Mori W, Nagai Y, Mimura K, Kumata K, Kikuchi T, Shimozawa A, Mishra SK, Yamaguchi Y, Shimizu H, Kakita A, Takuwa H, Shinotoh H, Shimada H, Kimura Y, Ichise M, Suhara T, Minamimoto T, Sahara N, Kawamura K, Zhang MR, Hasegawa M, Higuchi M (2024) Imaging alpha-synuclein pathologies in animal models and patients with Parkinson\u2019s and related diseases. Neuron 112(2540\u20132557):e8. https:\/\/doi.org\/10.1016\/j.neuron.2024.05.006","journal-title":"Neuron"},{"key":"1538_CR24","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study G (2004) Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351:2498\u2013508. https:\/\/doi.org\/10.1056\/NEJMoa033447","journal-title":"N Engl J Med"},{"key":"1538_CR25","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00259-018-4029-9","volume":"45","author":"S Fanti","year":"2018","unstructured":"Fanti S, Bonfiglioli R, Decristoforo C (2018) Highlights of the 30th annual congress of the EANM, Vienna 2017: \u201cyes we can - make nuclear medicine great again.\u201d Eur J Nucl Med Mol Imaging 45:1781\u20131794. https:\/\/doi.org\/10.1007\/s00259-018-4029-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1538_CR26","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/sj.emboj.7600211","volume":"23","author":"CO Fernandez","year":"2004","unstructured":"Fernandez CO, Hoyer W, Zweckstetter M, Jares-Erijman EA, Subramaniam V, Griesinger C, Jovin TM (2004) NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J 23:2039\u201346. https:\/\/doi.org\/10.1038\/sj.emboj.7600211","journal-title":"EMBO J"},{"issue":"1\u20133","key":"1538_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejphar.2009.06.042","volume":"617","author":"MT Fodero-Tavoletti","year":"2009","unstructured":"Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, Masters CL, Cappai R, Yanai K, Villemagne VL (2009) In vitro characterisation of BF227 binding to alpha-synuclein\/Lewy bodies. Eur J Pharmacol 617(1\u20133):54\u20138. https:\/\/doi.org\/10.1016\/j.ejphar.2009.06.042","journal-title":"Eur J Pharmacol"},{"key":"1538_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/alz.043249","author":"EV Francesca Capotosti","year":"2020","unstructured":"Francesca Capotosti EV, Molette J, Tsika E, Ravache M, Juergens T, Melo A, dos Santos V, Darmency KP, Heiko Kroth MC, Hliva V, Sol O, Pfeifer A, Kosco-Vilbois M (2020) Developing a novel alpha-synuclein positron emission tomography (PET) tracer for the diagnosis of synucleinopathies. Alzheimer\u2019s Dement. https:\/\/doi.org\/10.1002\/alz.043249","journal-title":"Alzheimer\u2019s Dement"},{"key":"1538_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/alz.064680","author":"EV Francesca Capotosti","year":"2022","unstructured":"Francesca Capotosti EV, Molette J, Ravache M, Delgado C, Kocher J, Pittet L, Vallet C, Serra A, Piorkowska K, Dimitrakopoulos IK, Luthi-Carter R, Tsika E, Touilloux T, Hliva V, Smith R, Hansson O, Streffer J, Pfeifer A, Kosco-Vilbois M (2022) Discovery of [18F]ACI-12589, a novel and promising PET-tracer for alpha-synuclein. Alzheimer\u2019s Dement. https:\/\/doi.org\/10.1002\/alz.064680","journal-title":"Alzheimer\u2019s Dement"},{"key":"1538_CR30","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/bpa.12046","volume":"23","author":"S George","year":"2013","unstructured":"George S, Rey NL, Reichenbach N, Steiner JA, Brundin P (2013) Alpha-synuclein: the long distance runner. Brain Pathol 23:350\u20137. https:\/\/doi.org\/10.1111\/bpa.12046","journal-title":"Brain Pathol"},{"key":"1538_CR31","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1172\/JCI66029","volume":"123","author":"TE Golde","year":"2013","unstructured":"Golde TE, Borchelt DR, Giasson BI, Lewis J (2013) Thinking laterally about neurodegenerative proteinopathies. J Clin Invest 123:1847\u201355. https:\/\/doi.org\/10.1172\/JCI66029","journal-title":"J Clin Invest"},{"key":"1538_CR32","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.euroneuro.2011.08.008","volume":"21","author":"A Gustavsson","year":"2011","unstructured":"Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jonsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercke A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, Van Den Bergh P, Van Os J, Vos P, Xu W, Wittchen HU, Jonsson B, Olesen J, Group CD (2011) Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:718\u201379. https:\/\/doi.org\/10.1016\/j.euroneuro.2011.08.008","journal-title":"Eur Neuropsychopharmacol"},{"key":"1538_CR33","unstructured":"Hans-J\u00fcrgen Wester BHY (2019) Compounds binding to neuropathological aggregates. US20170157274A1,"},{"key":"1538_CR34","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1385\/JMN:24:3:343","volume":"24","author":"M Hashimoto","year":"2004","unstructured":"Hashimoto M, Kawahara K, Bar-On P, Rockenstein E, Crews L, Masliah E (2004) The role of alpha-synuclein assembly and metabolism in the pathogenesis of Lewy body disease. J Mol Neurosci 24:343\u201352. https:\/\/doi.org\/10.1385\/JMN:24:3:343","journal-title":"J Mol Neurosci"},{"key":"1538_CR35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2009.08.007","volume":"16","author":"CH Hawkes","year":"2010","unstructured":"Hawkes CH, Del Tredici K, Braak H (2010) A timeline for Parkinson\u2019s disease. Parkinsonism Relat Disord 16:79\u201384. https:\/\/doi.org\/10.1016\/j.parkreldis.2009.08.007","journal-title":"Parkinsonism Relat Disord"},{"key":"1538_CR36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years. Mov Disord 23:837\u201344. https:\/\/doi.org\/10.1002\/mds.21956","journal-title":"Mov Disord"},{"key":"1538_CR37","doi-asserted-by":"publisher","first-page":"38173","DOI":"10.1074\/jbc.M110.127753","volume":"285","author":"MP Hinault","year":"2010","unstructured":"Hinault MP, Cuendet AF, Mattoo RU, Mensi M, Dietler G, Lashuel HA, Goloubinoff P (2010) Stable alpha-synuclein oligomers strongly inhibit chaperone activity of the Hsp70 system by weak interactions with J-domain co-chaperones. J Biol Chem 285:38173\u201382. https:\/\/doi.org\/10.1074\/jbc.M110.127753","journal-title":"J Biol Chem"},{"key":"1538_CR38","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1683494","author":"B Hooshyar Yousefi","year":"2019","unstructured":"Hooshyar Yousefi B, Shi K, Arzberger T, Wester HJ, Schwaiger M, Yakushev I, Weber W (2019) Translational study of a novel alpha-synuclein PET tracer designed for first-in-human investigating. Nuklearmedizin. https:\/\/doi.org\/10.1055\/s-0039-1683494","journal-title":"Nuklearmedizin"},{"key":"1538_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/s0002-9440(10)64553-1","volume":"157","author":"LJ Hsu","year":"2000","unstructured":"Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong J, Takenouchi T, Hashimoto M, Masliah E (2000) Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 157:401\u201310. https:\/\/doi.org\/10.1016\/s0002-9440(10)64553-1","journal-title":"Am J Pathol"},{"key":"1538_CR40","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1212\/wnl.57.8.1497","volume":"57","author":"AJ Hughes","year":"2001","unstructured":"Hughes AJ, Daniel SE, Lees AJ (2001) Improved accuracy of clinical diagnosis of Lewy body Parkinson\u2019s disease. Neurology 57:1497\u20139. https:\/\/doi.org\/10.1212\/wnl.57.8.1497","journal-title":"Neurology"},{"key":"1538_CR41","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s11307-023-01814-9","volume":"25","author":"B Janssen","year":"2023","unstructured":"Janssen B, Tian G, Lengyel-Zhand Z, Hsieh CJ, Lougee MG, Riad A, Xu K, Hou C, Weng CC, Lopresti BJ, Kim HJ, Pagar VV, Ferrie JJ, Garcia BA, Mathis CA, Luk K, Petersson EJ, Mach RH (2023) Identification of a putative alpha-synuclein radioligand using an in silico similarity search. Mol Imaging Biol 25:704\u2013719. https:\/\/doi.org\/10.1007\/s11307-023-01814-9","journal-title":"Mol Imaging Biol"},{"key":"1538_CR42","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1021\/acschemneuro.0c00523","volume":"11","author":"S Kaide","year":"2020","unstructured":"Kaide S, Watanabe H, Shimizu Y, Iikuni S, Nakamoto Y, Hasegawa M, Itoh K, Ono M (2020) Identification and evaluation of bisquinoline scaffold as a new candidate for alpha-synuclein-PET imaging. ACS Chem Neurosci 11:4254\u20134261. https:\/\/doi.org\/10.1021\/acschemneuro.0c00523","journal-title":"ACS Chem Neurosci"},{"key":"1538_CR43","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1038\/emboj.2009.257","volume":"28","author":"DP Karpinar","year":"2009","unstructured":"Karpinar DP, Balija MB, Kugler S, Opazo F, Rezaei-Ghaleh N, Wender N, Kim HY, Taschenberger G, Falkenburger BH, Heise H, Kumar A, Riedel D, Fichtner L, Voigt A, Braus GH, Giller K, Becker S, Herzig A, Baldus M, Jackle H, Eimer S, Schulz JB, Griesinger C, Zweckstetter M (2009) Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson\u2019s disease models. EMBO J 28:3256\u201368. https:\/\/doi.org\/10.1038\/emboj.2009.257","journal-title":"EMBO J"},{"issue":"Pt 6","key":"1538_CR44","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/brain\/awq091","volume":"133","author":"A Kikuchi","year":"2010","unstructured":"Kikuchi A, Takeda A, Okamura N, Tashiro M, Hasegawa T, Furumoto S, Kobayashi M, Sugeno N, Baba T, Miki Y, Mori F, Wakabayashi K, Funaki Y, Iwata R, Takahashi S, Fukuda H, Arai H, Kudo Y, Yanai K, Itoyama Y (2010) In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 133(Pt 6):1772\u20138. https:\/\/doi.org\/10.1093\/brain\/awq091","journal-title":"Brain"},{"key":"1538_CR45","doi-asserted-by":"publisher","first-page":"12185","DOI":"10.1021\/acs.jmedchem.3c00779","volume":"66","author":"HY Kim","year":"2023","unstructured":"Kim HY, Chia WK, Hsieh CJ, Saturnino Guarino D, Graham TJA, Lengyel-Zhand Z, Schneider M, Tomita C, Lougee MG, Kim HJ, Pagar VV, Lee H, Hou C, Garcia BA, Petersson EJ, O\u2019shea J, Kotzbauer PT, Mathis CA, Lee VM, Luk KC, Mach RH (2023) A novel brain PET radiotracer for imaging alpha synuclein fibrils in multiple system atrophy. J Med Chem 66:12185\u201312202. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00779","journal-title":"J Med Chem"},{"key":"1538_CR46","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/mds.27013","volume":"32","author":"S Koga","year":"2017","unstructured":"Koga S, Ono M, Sahara N, Higuchi M, Dickson DW (2017) Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to alpha-synuclein pathology. Mov Disord 32:884\u2013892. https:\/\/doi.org\/10.1002\/mds.27013","journal-title":"Mov Disord"},{"issue":"9","key":"1538_CR47","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3390\/ph14090847","volume":"14","author":"S Korat","year":"2021","unstructured":"Korat S, Bidesi NSR, Bonanno F, Di Nanni A, Hoang ANN, Herfert K, Maurer A, Battisti UM, Bowden GD, Thonon D, Vugts D, Windhorst AD, Herth MM (2021) Alpha-synuclein PET tracer development-an overview about current efforts. Pharmaceuticals (Basel) 14(9):847. https:\/\/doi.org\/10.3390\/ph14090847","journal-title":"Pharmaceuticals (Basel)"},{"key":"1538_CR48","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2967\/jnumed.106.037556","volume":"48","author":"Y Kudo","year":"2007","unstructured":"Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, Itoh M, Iwata R, Yanai K, Arai H (2007) 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer\u2019s disease patients. J Nucl Med 48:553\u201361. https:\/\/doi.org\/10.2967\/jnumed.106.037556","journal-title":"J Nucl Med"},{"key":"1538_CR49","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s00259-020-05133-x","volume":"48","author":"L Kuebler","year":"2021","unstructured":"Kuebler L, Buss S, Leonov A, Ryazanov S, Schmidt F, Maurer A, Weckbecker D, Landau AM, Lillethorup TP, Bleher D, Saw RS, Pichler BJ, Griesinger C, Giese A, Herfert K (2021) [(11)C]MODAG-001-towards a PET tracer targeting alpha-synuclein aggregates. Eur J Nucl Med Mol Imaging 48:1759\u20131772. https:\/\/doi.org\/10.1007\/s00259-020-05133-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1538_CR50","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, Nordberg A (2019) Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry 24:1112\u20131134. https:\/\/doi.org\/10.1038\/s41380-018-0342-8","journal-title":"Mol Psychiatry"},{"key":"1538_CR51","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2174\/1567205011666141107154201","volume":"11","author":"E Levigoureux","year":"2014","unstructured":"Levigoureux E, Lancelot S, Bouillot C, Chauveau F, Verdurand M, Verchere J, Billard T, Baron T, Zimmer L (2014) Binding of the PET radiotracer [(1)(8)F]BF227 does not reflect the presence of alpha-synuclein aggregates in transgenic mice. Curr Alzheimer Res 11:955\u201360. https:\/\/doi.org\/10.2174\/1567205011666141107154201","journal-title":"Curr Alzheimer Res"},{"key":"1538_CR52","doi-asserted-by":"publisher","first-page":"12924","DOI":"10.1074\/jbc.M306390200","volume":"279","author":"E Lindersson","year":"2004","unstructured":"Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB, Jensen PH (2004) Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 279:12924\u201334. https:\/\/doi.org\/10.1074\/jbc.M306390200","journal-title":"J Biol Chem"},{"key":"1538_CR53","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1053\/j.semnuclmed.2017.06.003","volume":"47","author":"CA Mathis","year":"2017","unstructured":"Mathis CA, Lopresti BJ, Ikonomovic MD, Klunk WE (2017) Small-molecule PET tracers for imaging proteinopathies. Semin Nucl Med 47:553\u2013575. https:\/\/doi.org\/10.1053\/j.semnuclmed.2017.06.003","journal-title":"Semin Nucl Med"},{"key":"1538_CR54","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1002\/mds.29186","volume":"37","author":"K Matsuoka","year":"2022","unstructured":"Matsuoka K, Ono M, Takado Y, Hirata K, Endo H, Ohfusa T, Kojima T, Yamamoto T, Onishi T, Orihara A, Tagai K, Takahata K, Seki C, Shinotoh H, Kawamura K, Shimizu H, Shimada H, Kakita A, Zhang MR, Suhara T, Higuchi M (2022) High-contrast imaging of alpha-synuclein pathologies in living patients with multiple system atrophy. Mov Disord 37:2159\u20132161. https:\/\/doi.org\/10.1002\/mds.29186","journal-title":"Mov Disord"},{"key":"1538_CR55","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/cmdc.201900689","volume":"15","author":"A Maurer","year":"2020","unstructured":"Maurer A, Leonov A, Ryazanov S, Herfert K, Kuebler L, Buss S, Schmidt F, Weckbecker D, Linder R, Bender D, Giese A, Pichler BJ, Griesinger C (2020) (11) C Radiolabeling of anle253b: a putative PET tracer for Parkinson\u2019s disease that binds to alpha-synuclein fibrils in vitro and crosses the blood-brain barrier. ChemMedChem 15:411\u2013415. https:\/\/doi.org\/10.1002\/cmdc.201900689","journal-title":"ChemMedChem"},{"issue":"Suppl 1","key":"1538_CR56","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/S1353-8020(13)70017-8","volume":"20","author":"H McCann","year":"2014","unstructured":"McCann H, Stevens CH, Cartwright H, Halliday GM (2014) Alpha-synucleinopathy phenotypes. Parkinsonism Relat Disord 20(Suppl 1):S62-7. https:\/\/doi.org\/10.1016\/S1353-8020(13)70017-8","journal-title":"Parkinsonism Relat Disord"},{"key":"1538_CR57","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/ene.13398","volume":"24","author":"TH Mertsalmi","year":"2017","unstructured":"Mertsalmi TH, Aho VTE, Pereira PAB, Paulin L, Pekkonen E, Auvinen P, Scheperjans F (2017) More than constipation - bowel symptoms in Parkinson\u2019s disease and their connection to gut microbiota. Eur J Neurol 24:1375\u20131383. https:\/\/doi.org\/10.1111\/ene.13398","journal-title":"Eur J Neurol"},{"key":"1538_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2020.147131","volume":"1749","author":"P Miranda-Azpiazu","year":"2020","unstructured":"Miranda-Azpiazu P, Svedberg M, Higuchi M, Ono M, Jia Z, Sunnemark D, Elmore CS, Schou M, Varrone A (2020) Identification and in vitro characterization of C05\u201301, a PBB3 derivative with improved affinity for alpha-synuclein. Brain Res 1749:147131. https:\/\/doi.org\/10.1016\/j.brainres.2020.147131","journal-title":"Brain Res"},{"key":"1538_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2024.105760","volume":"177","author":"S Negi","year":"2024","unstructured":"Negi S, Khurana N, Duggal N (2024) The misfolding mystery: alpha-synuclein and the pathogenesis of Parkinson\u2019s disease. Neurochem Int 177:105760. https:\/\/doi.org\/10.1016\/j.neuint.2024.105760","journal-title":"Neurochem Int"},{"key":"1538_CR60","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1474-4422(04)00827-0","volume":"3","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Perl DP, DeMartino GN, McNaught KS (2004) Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 3:496\u2013503. https:\/\/doi.org\/10.1016\/S1474-4422(04)00827-0","journal-title":"Lancet Neurol"},{"key":"1538_CR61","doi-asserted-by":"publisher","first-page":"44305","DOI":"10.1039\/C6RA02710E","volume":"6","author":"M Ono","year":"2016","unstructured":"Ono M, Doi Y, Watanabe H, Ihara M, Ozaki A, Saji H (2016) Structure\u2013activity relationships of radioiodinated diphenyl derivatives with different conjugated double bonds as ligands for \u03b1-synuclein aggregates. RSC Adv 6:44305\u201344312. https:\/\/doi.org\/10.1039\/C6RA02710E","journal-title":"RSC Adv"},{"key":"1538_CR62","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","volume":"287","author":"Parkinson Study G","year":"2002","unstructured":"Parkinson Study G (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287:1653\u201361. https:\/\/doi.org\/10.1001\/jama.287.13.1653","journal-title":"JAMA"},{"issue":"23","key":"1538_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/chem.202303921","volume":"30","author":"A Pees","year":"2024","unstructured":"Pees A, Tong J, Birudaraju S, Munot YS, Liang SH, Saturnino Guarino D, Mach RH, Mathis CA, Vasdev N (2024) Development of pyridothiophene compounds for PET imaging of alpha-synuclein. Chemistry 30(23):e202303921. https:\/\/doi.org\/10.1002\/chem.202303921","journal-title":"Chemistry"},{"key":"1538_CR64","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/mds.27029","volume":"32","author":"A Perez-Soriano","year":"2017","unstructured":"Perez-Soriano A, Arena JE, Dinelle K, Miao Q, Mckenzie J, Neilson N, Puschmann A, Schaffer P, Shinotoh H, Smith-Forrester J, Shahinfard E, Vafai N, Wile D, Wszolek Z, Higuchi M, Sossi V, Stoessl AJ (2017) PBB3 imaging in Parkinsonian disorders: evidence for binding to tau and other proteins. Mov Disord 32:1016\u20131024. https:\/\/doi.org\/10.1002\/mds.27029","journal-title":"Mov Disord"},{"key":"1538_CR65","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nucmedbio.2022.08.001","volume":"114\u2013115","author":"NR Raval","year":"2022","unstructured":"Raval NR, Madsen CA, Shalgunov V, Nasser A, Battisti UM, Beaman EE, Juhl M, Jorgensen LM, Herth MM, Hansen HD, Plaven-Sigray P, Knudsen GM (2022) Evaluation of the alpha-synuclein PET radiotracer (d(3))-[(11)C]MODAG-001 in pigs. Nucl Med Biol 114\u2013115:42\u201348. https:\/\/doi.org\/10.1016\/j.nucmedbio.2022.08.001","journal-title":"Nucl Med Biol"},{"issue":"6","key":"1538_CR66","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","volume":"86","author":"G Rizzo","year":"2016","unstructured":"Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G (2016) Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 86(6):566\u201376. https:\/\/doi.org\/10.1212\/WNL.0000000000002350","journal-title":"Neurology"},{"key":"1538_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.108985","volume":"208","author":"S Roshanbin","year":"2022","unstructured":"Roshanbin S, Xiong M, Hultqvist G, Soderberg L, Zachrisson O, Meier S, Ekmark-Lewen S, Bergstrom J, Ingelsson M, Sehlin D, Syvanen S (2022) In vivo imaging of alpha-synuclein with antibody-based PET. Neuropharmacology 208:108985. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.108985","journal-title":"Neuropharmacology"},{"issue":"22","key":"1538_CR68","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1021\/acschemneuro.4c00493","volume":"15","author":"D Saturnino Guarino","year":"2024","unstructured":"Saturnino Guarino D, Miranda Azpiazu P, Sunnemark D, Elmore CS, Bergare J, Artelsmair M, Nordvall G, Forsberg Moren A, Jia Z, Cortes-Gonzalez M, Mach RH, Wilcox KC, Finnema S, Schou M, Varrone A (2024) Identification and in vitro and in vivo characterization of KAC-501 as a potential alpha-SYNUCLEIN PET Radioligand. ACS Chem Neurosci 15(22):4210\u20134219. https:\/\/doi.org\/10.1021\/acschemneuro.4c00493","journal-title":"ACS Chem Neurosci"},{"issue":"9942","key":"1538_CR69","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(14)61010-2","volume":"384","author":"AH Schapira","year":"2014","unstructured":"Schapira AH, Olanow CW, Greenamyre JT, Bezard E (2014) Slowing of neurodegeneration in Parkinson\u2019s disease and Huntington\u2019s disease: future therapeutic perspectives. Lancet 384(9942):545\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(14)61010-2","journal-title":"Lancet"},{"issue":"24","key":"1538_CR70","doi-asserted-by":"publisher","first-page":"8083","DOI":"10.1523\/JNEUROSCI.1091-10.2010","volume":"30","author":"DA Scott","year":"2010","unstructured":"Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S (2010) A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci 30(24):8083\u201395. https:\/\/doi.org\/10.1523\/JNEUROSCI.1091-10.2010","journal-title":"J Neurosci"},{"key":"1538_CR71","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.2967\/jnumed.113.136515","volume":"55","author":"M Shah","year":"2014","unstructured":"Shah M, Seibyl J, Cartier A, Bhatt R, Catafau AM (2014) Molecular imaging insights into neurodegeneration: focus on alpha-synuclein radiotracers. J Nucl Med 55:1397\u2013400. https:\/\/doi.org\/10.2967\/jnumed.113.136515","journal-title":"J Nucl Med"},{"key":"1538_CR72","doi-asserted-by":"publisher","first-page":"6750","DOI":"10.1038\/s41467-023-42305-3","volume":"14","author":"R Smith","year":"2023","unstructured":"Smith R, Capotosti F, Schain M, Ohlsson T, Vokali E, Molette J, Touilloux T, Hliva V, Dimitrakopoulos IK, Puschmann A, Jogi J, Svenningsson P, Andreasson M, Sandiego C, Russell DS, Miranda-Azpiazu P, Halldin C, Stomrud E, Hall S, Bratteby K, Tampio L\u2019estrade E, Luthi-Carter R, Pfeifer A, Kosco-Vilbois M, Streffer J, Hansson O (2023) The alpha-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat Commun 14:6750. https:\/\/doi.org\/10.1038\/s41467-023-42305-3","journal-title":"Nat Commun"},{"key":"1538_CR73","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/s0304-3940(98)00504-7","volume":"251","author":"MG Spillantini","year":"1998","unstructured":"Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson\u2019s disease and dementia with Lewy bodies. Neurosci Lett 251:205\u20138. https:\/\/doi.org\/10.1016\/s0304-3940(98)00504-7","journal-title":"Neurosci Lett"},{"issue":"2","key":"1538_CR74","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009399","volume":"2","author":"L Stefanis","year":"2012","unstructured":"Stefanis L (2012) Alpha-Synuclein in Parkinson\u2019s disease. Cold Spring Harb Perspect Med 2(2):a009399. https:\/\/doi.org\/10.1101\/cshperspect.a009399","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1538_CR75","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1074\/jbc.M310994200","volume":"279","author":"M Tanaka","year":"2004","unstructured":"Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM (2004) Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 279:4625\u201331. https:\/\/doi.org\/10.1074\/jbc.M310994200","journal-title":"J Biol Chem"},{"key":"1538_CR76","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1523\/JNEUROSCI.1871-20.2020","volume":"41","author":"D Trudler","year":"2021","unstructured":"Trudler D, Sanz-Blasco S, Eisele YS, Ghatak S, Bodhinathan K, Akhtar MW, Lynch WP, Pina-Crespo JC, Talantova M, Kelly JW, Lipton SA (2021) \u03b1-Synuclein oligomers induce glutamate release from astrocytes and excessive extrasynaptic NMDAR activity in neurons, thus contributing to synapse loss. J Neurosci 41:2264\u20132273. https:\/\/doi.org\/10.1523\/JNEUROSCI.1871-20.2020","journal-title":"J Neurosci"},{"key":"1538_CR77","doi-asserted-by":"publisher","first-page":"6892","DOI":"10.1038\/s41467-023-42705-5","volume":"14","author":"N Uemura","year":"2023","unstructured":"Uemura N, Marotta NP, Ara J, Meymand ES, Zhang B, Kameda H, Koike M, Luk KC, Trojanowski JQ, Lee VM (2023) alpha-Synuclein aggregates amplified from patient-derived Lewy bodies recapitulate Lewy body diseases in mice. Nat Commun 14:6892. https:\/\/doi.org\/10.1038\/s41467-023-42705-5","journal-title":"Nat Commun"},{"issue":"4","key":"1538_CR78","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3390\/molecules25040977","volume":"25","author":"BC Uzuegbunam","year":"2020","unstructured":"Uzuegbunam BC, Librizzi D, Hooshyar Yousefi B (2020) PET radiopharmaceuticals for Alzheimer\u2019s disease and Parkinson\u2019s disease diagnosis, the current and future landscape. Molecules 25(4):977. https:\/\/doi.org\/10.3390\/molecules25040977","journal-title":"Molecules"},{"key":"1538_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.830704","volume":"14","author":"BC Uzuegbunam","year":"2022","unstructured":"Uzuegbunam BC, Li J, Paslawski W, Weber W, Svenningsson P, Agren H, Yousefi BH (2022) Toward novel [(18)F]Fluorine-labeled radiotracers for the imaging of alpha-synuclein fibrils. Front Aging Neurosci 14:830704. https:\/\/doi.org\/10.3389\/fnagi.2022.830704","journal-title":"Front Aging Neurosci"},{"issue":"22","key":"1538_CR80","doi-asserted-by":"publisher","first-page":"16445","DOI":"10.3390\/ijms242216445","volume":"24","author":"BC Uzuegbunam","year":"2023","unstructured":"Uzuegbunam BC, Li J, Paslawski W, Weber W, Svenningsson P, Agren H, Hooshyar Yousefi B (2023) In silico and in vitro study towards the rational design of 4,4\u2019-disarylbisthiazoles as a selective alpha-synucleinopathy biomarker. Int J Mol Sci 24(22):16445. https:\/\/doi.org\/10.3390\/ijms242216445","journal-title":"Int J Mol Sci"},{"key":"1538_CR81","doi-asserted-by":"publisher","first-page":"9165458","DOI":"10.1155\/2018\/9165458","volume":"2018","author":"M Verdurand","year":"2018","unstructured":"Verdurand M, Levigoureux E, Lancelot S, Zeinyeh W, Billard T, Quadrio I, Perret-Liaudet A, Zimmer L, Chauveau F (2018a) Amyloid-beta radiotracer [(18)F]BF-227 does not bind to cytoplasmic glial inclusions of postmortem multiple system atrophy brain tissue. Contrast Media Mol Imaging 2018:9165458. https:\/\/doi.org\/10.1155\/2018\/9165458","journal-title":"Contrast Media Mol Imaging"},{"key":"1538_CR82","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1021\/acs.molpharmaceut.8b00229","volume":"15","author":"M Verdurand","year":"2018","unstructured":"Verdurand M, Levigoureux E, Zeinyeh W, Berthier L, Mendjel-Herda M, Cadarossanesaib F, Bouillot C, Iecker T, Terreux R, Lancelot S, Chauveau F, Billard T, Zimmer L (2018b) In silico, in vitro, and in vivo evaluation of new candidates for alpha-synuclein PET imaging. Mol Pharm 15:3153\u20133166. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00229","journal-title":"Mol Pharm"},{"issue":"7","key":"1538_CR83","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41582-018-0021-z","volume":"14","author":"VL Villemagne","year":"2018","unstructured":"Villemagne VL, Dore V, Burnham SC, Masters CL, Rowe CC (2018) Author correction: imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol 14(7):446. https:\/\/doi.org\/10.1038\/s41582-018-0021-z","journal-title":"Nat Rev Neurol"},{"key":"1538_CR84","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/B978-0-444-63945-5.00017-9","volume":"153","author":"L Volpicelli-Daley","year":"2018","unstructured":"Volpicelli-Daley L, Brundin P (2018) Prion-like propagation of pathology in Parkinson disease. Handb Clin Neurol 153:321\u2013335. https:\/\/doi.org\/10.1016\/B978-0-444-63945-5.00017-9","journal-title":"Handb Clin Neurol"},{"key":"1538_CR85","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, Prix C, Pan-Montojo F, Bertsch U, Mitteregger-Kretzschmar G, Geissen M, Eiden M, Leidel F, Hirschberger T, Deeg AA, Krauth JJ, Zinth W, Tavan P, Pilger J, Zweckstetter M, Frank T, Bahr M, Weishaupt JH, Uhr M, Urlaub H, Teichmann U, Samwer M, Botzel K, Groschup M, Kretzschmar H, Griesinger C, Giese A (2013) Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol 125:795\u2013813. https:\/\/doi.org\/10.1007\/s00401-013-1114-9","journal-title":"Acta Neuropathol"},{"key":"1538_CR86","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1016\/j.bmc.2017.10.010","volume":"25","author":"H Watanabe","year":"2017","unstructured":"Watanabe H, Ariyoshi T, Ozaki A, Ihara M, Ono M, Saji H (2017) Synthesis and biological evaluation of novel radioiodinated benzimidazole derivatives for imaging alpha-synuclein aggregates. Bioorg Med Chem 25:6398\u20136403. https:\/\/doi.org\/10.1016\/j.bmc.2017.10.010","journal-title":"Bioorg Med Chem"},{"key":"1538_CR87","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1073\/pnas.1100976108","volume":"108","author":"B Winner","year":"2011","unstructured":"Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108:4194\u20139. https:\/\/doi.org\/10.1073\/pnas.1100976108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1538_CR88","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.apmr.2004.09.010","volume":"86","author":"A Winogrodzka","year":"2005","unstructured":"Winogrodzka A, Wagenaar RC, Booij J, Wolters EC (2005) Rigidity and bradykinesia reduce interlimb coordination in Parkinsonian gait. Arch Phys Med Rehabil 86:183\u20139. https:\/\/doi.org\/10.1016\/j.apmr.2004.09.010","journal-title":"Arch Phys Med Rehabil"},{"key":"1538_CR89","doi-asserted-by":"publisher","first-page":"19509","DOI":"10.1074\/jbc.274.28.19509","volume":"274","author":"SJ Wood","year":"1999","unstructured":"Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL (1999) alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson\u2019s disease. J Biol Chem 274:19509\u201312. https:\/\/doi.org\/10.1074\/jbc.274.28.19509","journal-title":"J Biol Chem"},{"issue":"16","key":"1538_CR90","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1016\/j.cell.2023.06.004","volume":"186","author":"J Xiang","year":"2023","unstructured":"Xiang J, Tao Y, Xia Y, Luo S, Zhao Q, Li B, Zhang X, Sun Y, Xia W, Zhang M, Kang SS, Ahn EH, Liu X, Xie F, Guan Y, Yang JJ, Bu L, Wu S, Wang X, Cao X, Liu C, Zhang Z, Li D, Ye K (2023) Development of an alpha-synuclein positron emission tomography tracer for imaging synucleinopathies. Cell 186(16):3350-3367.e19. https:\/\/doi.org\/10.1016\/j.cell.2023.06.004","journal-title":"Cell"},{"issue":"4","key":"1538_CR91","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41401-019-0304-y","volume":"41","author":"MM Xu","year":"2020","unstructured":"Xu MM, Ryan P, Rudrawar S, Quinn RJ, Zhang HY, Mellick GD (2020) Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein. Acta Pharmacol Sin 41(4):483\u2013498. https:\/\/doi.org\/10.1038\/s41401-019-0304-y","journal-title":"Acta Pharmacol Sin"},{"key":"1538_CR92","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1074\/jbc.RA118.004471","volume":"294","author":"TR Yamasaki","year":"2019","unstructured":"Yamasaki TR, Holmes BB, Furman JL, Dhavale DD, Su BW, Song ES, Cairns NJ, Kotzbauer PT, Diamond MI (2019) Parkinson\u2019s disease and multiple system atrophy have distinct alpha-synuclein seed characteristics. J Biol Chem 294:1045\u20131058. https:\/\/doi.org\/10.1074\/jbc.RA118.004471","journal-title":"J Biol Chem"},{"issue":"23","key":"1538_CR93","doi-asserted-by":"publisher","first-page":"14753","DOI":"10.3390\/ijms232314753","volume":"23","author":"S Yi","year":"2022","unstructured":"Yi S, Wang L, Wang H, Ho MS, Zhang S (2022) Pathogenesis of alpha-synuclein in Parkinson\u2019s disease: from a neuron-glia crosstalk perspective. Int J Mol Sci 23(23):14753. https:\/\/doi.org\/10.3390\/ijms232314753","journal-title":"Int J Mol Sci"},{"key":"1538_CR94","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1016\/j.bmc.2012.06.023","volume":"20","author":"L Yu","year":"2012","unstructured":"Yu L, Cui J, Padakanti PK, Engel L, Bagchi DP, Kotzbauer PT, Tu Z (2012) Synthesis and in vitro evaluation of alpha-synuclein ligands. Bioorg Med Chem 20:4625\u201334. https:\/\/doi.org\/10.1016\/j.bmc.2012.06.023","journal-title":"Bioorg Med Chem"},{"key":"1538_CR95","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/108029","volume":"2015","author":"M Zaltieri","year":"2015","unstructured":"Zaltieri M, Longhena F, Pizzi M, Missale C, Spano P, Bellucci A (2015) Mitochondrial dysfunction and alpha-synuclein synaptic pathology in Parkinson\u2019s disease: who\u2019s on first? Parkinsons Dis 2015:108029. https:\/\/doi.org\/10.1155\/2015\/108029","journal-title":"Parkinsons Dis"},{"key":"1538_CR96","doi-asserted-by":"publisher","first-page":"12695","DOI":"10.1021\/acs.jmedchem.4c00686","volume":"67","author":"Q Zeng","year":"2024","unstructured":"Zeng Q, Zhang X, Li Y, Zhang Q, Dai J, Yan XX, Liu Y, Zhang J, Liu S, Cui M (2024) Discovery and evaluation of Imidazo[2,1-b][1,3,4]thiadiazole derivatives as new candidates for alpha-synuclein PET imaging. J Med Chem 67:12695\u201312710. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00686","journal-title":"J Med Chem"},{"issue":"1","key":"1538_CR97","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/app4010066","volume":"4","author":"X Zhang","year":"2014","unstructured":"Zhang X, Jin H, Padakanti PK, Li J, Yang H, Fan J, Mach RH, Kotzbauer P, Tu Z (2014) Radiosynthesis and in vivo evaluation of two PET radioligands for imaging alpha-synuclein. Appl Sci (Basel) 4(1):66\u201378. https:\/\/doi.org\/10.3390\/app4010066","journal-title":"Appl Sci (Basel)"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-025-01538-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-025-01538-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-025-01538-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T08:17:51Z","timestamp":1746605871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-025-01538-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1538"],"URL":"https:\/\/doi.org\/10.1007\/s12272-025-01538-0","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}